Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;58(3):273-281.
doi: 10.1038/s41409-022-01883-4. Epub 2022 Dec 1.

Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity

Affiliations

Second allogeneic hematopoietic stem cell transplantation in patients with inborn errors of immunity

Alexandra Laberko et al. Bone Marrow Transplant. 2023 Mar.

Abstract

Graft failure (GF) remains a serious issue of hematopoietic stem cell transplantation (HSCT) in inborn errors of immunity (IEI). Second HSCT is the only salvage therapy for GF. There are no uniform strategies for the second HSCTs and limited data are available on the second HSCT outcomes. 48 patients with various IEI received second allogeneic HSCT from 2013 to 2020. Different conditioning regimens were used, divided into two main groups: containing myeloablative doses of busulfan/treosulfan (n = 19) and lymphoid irradiation 2-6 Gy (n = 22). Irradiation-containing conditioning was predominantly used in suspected immune-mediated rejection of the first graft. Matched unrelated donor was used in 28 patients, mismatched related in 18, and matched related in 1. 35 patients received TCRαβ/CD19 graft depletion. The median follow-up time was 2.4 years post-HSCT. One patient died at conditioning. The OS was 0.63 (95% CI: 0.41-0.85) after busulfan/treosulfan and 0.68 (95% CI: 0.48-0.88) after irradiation-based conditioning, p = 0.66. Active infection at HSCT significantly influenced OS: 0.43 (95% CI: 0.17-0.69) versus 0.73 (95% CI: 0.58-0.88) without infection, p = 0.004. The cumulative incidence of GF was 0.15 (95% CI: 0.08-0.29). To conclude, an individualized approach is required for the second HSCT in IEI. Low-dose lymphoid irradiation in suspected immune-mediated GF may be a feasible option.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Cumulative incidence of second HSCT graft failure depending on the type of conditioning regimen.
myeloablative conditioning (MAC) with irradiation, n = 10 (dotted curve) versus reduced intensity conditioning (RIC) with irradiation, n = 12 (solid curve) versus busulfan/treosulfan-based, n = 19 (dash curve).
Fig. 2
Fig. 2. Overall survival of the patients with IEI after second HSCT.
a Depending on the type of conditioning regimen: irradiation-based, n = 22 (solid curve) versus busulfan/treosulfan-based, n = 19 (dash curve). b Depending on the type of conditioning regimen: myeloablative conditioning (MAC) with irradiation, n = 10 (solid curve) versus reduced intensity conditioning (RIC) with irradiation, n = 12 (dash curve). c Depending on the presence of active infection at HSCT: with infection, n = 14 (dash curve) versus no infection, n = 34 (solid curve).

References

    1. Castagnoli R, Delmonte OM, Calzoni E, Notarangelo LD. Hematopoietic stem cell transplantation in primary immunodeficiency diseases: current status and future perspectives. Front Pediatr. 2019;7:295. doi: 10.3389/fped.2019.00295. - DOI - PMC - PubMed
    1. Lankester AC, Albert MH, Booth C, Gennery AR, Güngör T, Hönig M, et al. EBMT/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transpl. 2021;56:2052–62. doi: 10.1038/s41409-021-01378-8. - DOI - PMC - PubMed
    1. Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013;48:537–43. doi: 10.1038/bmt.2012.239. - DOI - PubMed
    1. Wehr C, Gennery AR, Lindemans C, Schulz A, Hoenig M, Marks R, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015;135:988–997.e6. doi: 10.1016/j.jaci.2014.11.029. - DOI - PubMed
    1. Chiesa R, Wang J, Blok HJ, Hazelaar S, Neven B, Moshous D, et al. Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults. Blood. 2020;136:1201–11. doi: 10.1182/blood.2020005590. - DOI - PubMed

MeSH terms